Table 6. Hazard ratios of probable Alzheimer's disease development among ε4 carriers reporting depression more than 2 years prior “lifetime” but without symptoms at baseline.

Predictor variables	Sample size with AD endpoint	Depression—lifetime × ε4 Main effects (unadjusted) Hazard ratio (95% CI)	Depression—lifetime × ε4 Main effects adjusteda Hazard ratio (95% CI)	Depression—lifetime × ε4 Main effects adjusted with AD medication use Hazard ratio (95% CI)
Lifetime depression × ε4	445	2.35 (1.52–3.61)**	3.65 (2.35–5.66)**	2.03 (1.30–3.16)*
Use of antidepressant	92	1.41 (0.740–2.67)	2.17 (1.12–4.21)*	1.39 (0.715–2.70)
Did not use antidepressant		1.76 (0.884–3.52)	2.70 (1.34–5.41)*	2.23 (1.11–4.48)*
Bupropion use	9	2.27 (0.235–21.94)	3.46 (0.252–47.56)	2.70 (0.148–49.44)
No bupropion use		2.28 (1.44–3.59)**	3.48 (2.19–5.52)**	1.99 (1.25–3.18)*
Citalopram use	26	4.75 (1.28–17.62)*	9.31 (2.33–37.24)*	3.44 (0.794–14.92)
No citalopram use		1.70 (1.01–2.84)*	2.63 (1.56–4.43)**	1.66 (0.980–2.82)
Escitalopram use	17	—	—	—
No escitalopram use		2.60 (1.68–4.02)**	4.03 (2.59–6.27)**	2.67 (1.45–3.55)**
Fluoxetine use	2	2.00 (0.125–31.98)	—	—
No fluoxetine use		2.40 (1.54–3.72)**	3.69 (2.36–5.76)**	2.05 (1.30–3.22)*
Mirtazapine use	9	0.106 (0.007–1.59)	0.321 (0.019–5.40)	3.33 (0.062–179.51)
No mirtazapine use		2.41 (1.55–3.75)**	3.80 (2.43–5.95)**	2.06 (1.31–3.25)*
Paroxetine use	7	6.11 (0.494–75.64)	10.18 (0.675–153.47)	12.09 (0.865–169.02)
No paroxetine use		2.21 (1.41–3.46)**	3.46 (2.20–5.45)**	1.88 (1.19–2.98)*
Sertraline use	9	—	—	—
No sertraline use		2.66 (1.72–4.11)**	4.27 (2.74–6.66)**	2.50 (1.60–3.91)**
Trazodone use	12	1.51 (0.135–16.76)	4.30 (0.266–69.45)	1.11 (0.073–16.71)
No trazodone use		2.36 (1.52–3.66)**	3.61 (2.31–5.65)**	2.03 (1.29–3.20)*

^—indicates sample size too small for analysis.

^aAdjusted for sex, age, education, and race.

^*Statistical significance at p < 0.05.

^**p < 0.001.